Chemomab Therapeutics Ltd2025财年第一财季实现净利润-3.31百万美元，同比增加15.35%

市场透视2025-05-24

5月24日，Chemomab Therapeutics Ltd（CMMB.US）公布财报，公告显示公司2025财年第一财季净利润为-3.31百万美元，同比增加15.35%；其中营业收入为0.00美元，每股基本收益为-0.14美元。从资产负债表来看，Chemomab Therapeutics Ltd（CMMB.US）总负债2.43百万美元，其中短期债务113001.72美元，资产负债比为5.28，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537715349?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-24 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537715349","market":"us","top_or_hot":-1,"title":"Chemomab Therapeutics Ltd2025财年第一财季实现净利润-3.31百万美元，同比增加15.35%","media":"市场透视","content":"<div>\n<p>5月24日，Chemomab Therapeutics Ltd（CMMB.US）公布财报，公告显示公司2025财年第一财季净利润为-3.31百万美元，同比增加15.35%；其中营业收入为0.00美元，每股基本收益为-0.14美元。从资产负债表来看，Chemomab Therapeutics Ltd（CMMB.US）总负债2.43百万美元，其中短期债务113001.72美元，资产负债比为5.28，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000103a489e560&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemomab Therapeutics Ltd2025财年第一财季实现净利润-3.31百万美元，同比增加15.35%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemomab Therapeutics Ltd2025财年第一财季实现净利润-3.31百万美元，同比增加15.35%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-24 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000103a489e560&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月24日，Chemomab Therapeutics Ltd（CMMB.US）公布财报，公告显示公司2025财年第一财季净利润为-3.31百万美元，同比增加15.35%；其中营业收入为0.00美元，每股基本收益为-0.14美元。从资产负债表来看，Chemomab Therapeutics Ltd（CMMB.US）总负债2.43百万美元，其中短期债务113001.72美元，资产负债比为5.28，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000103a489e560&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000103a489e560&s=b","article_id":"2537715349","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000103a489e560&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537715349","pubTimestamp":1748016037,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月24日，Chemomab Therapeutics Ltd公布财报，公告显示公司2025财年第一财季净利润为-3.31百万美元，同比增加15.35%；其中营业收入为0.00美元，每股基本收益为-0.14美元。从资产负债表来看，Chemomab Therapeutics Ltd总负债2.43百万美元，其中短期债务113001.72美元，资产负债比为5.28，流动比率为5.33。机构评级：截至2025年5月24日，当前有2家机构对Chemomab Therapeutics Ltd目标价做出预测，其中目标均价为8.50美元，其中最低目标价为7.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","CMMB":"Chemomab Therapeutics Ltd."},"translate_title":"Chemomab Therapeutics Ltd achieved net profit of-US $3.31 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 15.35%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CMMB":0.9},"content_text":"5月24日，Chemomab Therapeutics Ltd（CMMB.US）公布财报，公告显示公司2025财年第一财季净利润为-3.31百万美元，同比增加15.35%；其中营业收入为0.00美元，每股基本收益为-0.14美元。从资产负债表来看，Chemomab Therapeutics Ltd（CMMB.US）总负债2.43百万美元，其中短期债务113001.72美元，资产负债比为5.28，流动比率为5.33。机构评级：截至2025年5月24日，当前有2家机构对Chemomab Therapeutics Ltd目标价做出预测，其中目标均价为8.50美元，其中最低目标价为7.00美元，最高目标价为10.00美元。公司简介：Chemomab Therapeutics Ltd 是一家临床阶段的生物科技公司，专注于发现和开发针对具有迫切需求的纤维化相关疾病的治疗方法。该公司的候选药物CM-101是一种针对CCL24的单克隆抗体，已经证明可以通过新颖和独特的作用机制干预肝脏、皮肤和肺部纤维化的基础生物学过程。CM-101已经显示出有潜力治疗多种严重和危及生命的纤维化和炎症性疾病该公司正在同时推进三项针对CM-101用于治疗罕见纤维化病症的二期临床试验。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537715349","isCrawlerRequest":true}